What is Leerink Partnrs' Forecast for VYGR FY2029 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a research note issued to investors on Tuesday, May 6th. Leerink Partnrs analyst L. Nsongo anticipates that the company will post earnings of ($1.17) per share for the year. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share.

VYGR has been the subject of a number of other reports. Canaccord Genuity Group cut their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday, March 13th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. Wedbush reaffirmed an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Voyager Therapeutics has an average rating of "Buy" and an average target price of $13.97.

Voyager Therapeutics Stock Down 1.5%

Voyager Therapeutics stock traded down $0.05 during mid-day trading on Thursday, hitting $3.30. 327,648 shares of the company's stock were exchanged, compared to its average volume of 446,306. The company's 50 day simple moving average is $3.50 and its 200-day simple moving average is $4.89. Voyager Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $9.55. The firm has a market capitalization of $182.61 million, a P/E ratio of 4.65 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.

Insider Transactions at Voyager Therapeutics

In related news, CEO Alfred Sandrock sold 10,885 shares of the company's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now directly owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This represents a 2.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.39% of the company's stock.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Voyager Therapeutics by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 3,215,441 shares of the company's stock valued at $18,232,000 after buying an additional 29,014 shares during the last quarter. Farallon Capital Management LLC raised its stake in Voyager Therapeutics by 12.2% during the 4th quarter. Farallon Capital Management LLC now owns 2,570,700 shares of the company's stock valued at $14,576,000 after buying an additional 278,700 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Voyager Therapeutics by 24.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,380,615 shares of the company's stock worth $7,828,000 after purchasing an additional 275,571 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Voyager Therapeutics by 151.0% in the 4th quarter. Vestal Point Capital LP now owns 1,230,000 shares of the company's stock worth $6,974,000 after purchasing an additional 740,000 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Voyager Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock worth $6,149,000 after purchasing an additional 4,729 shares in the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.